#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children

Children are frequent carriers of pneumococci, which can cause both common non-invasive and more severe, life-threatening invasive pneumococcal diseases, especially in children under 1 year of age and in people over 65 years old. Almost a year ago, a pediatric indication for a 15-valent pneumococcal vaccine was approved, which is enriched with 2 new serotypes and, according to study results, appears to be potentially more effective even in protecting against serotype 3. So what are the vaccination options for healthy immunocompetent children, and what benefits does this vaccine offer for premature infants? Professor Roman Chlíbek, chair of the Czech Vaccinology Society ČLS JEP, answered these questions in his presentation at the June Interdisciplinary Conference of PLDD.
Source: Regular Vaccination 25. 8. 2023

News The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring

The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed the incidence of clinically significant changes in hematological or biochemical parameters in patients with moderate to severe atopic dermatitis.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 12. 2020

News Effectiveness of Idarucizumab Reversal Effect

It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody that binds dabigatran with high affinity. The drug was approved for clinical use based on an interim analysis of the results of 90 patients enrolled in the RE-VERSE AD study. What conclusions were drawn based on the results of the entire study population?
Source: Anticoagulant Treatment 21. 4. 2022

News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
Source: Non-Small Cell Lung Cancer 12. 9. 2022

News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice

The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
Source: Hematologic Malignancies 10. 3. 2021

News Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension

Can monotherapy with bimatoprost be sufficiently effective in controlling intraocular pressure in non-responders to previous treatments? This is the question posed by British researchers in the presented study.
Source: Treatment of Glaucoma 4. 5. 2020

News Basic Information on the Spread and Course of COVID-19 Infection in China: What We Know So Far?

Currently, we are experiencing a worldwide outbreak of COVID-19 infection caused by the SARS-CoV-2 virus, with the first cases identified in December 2019 in Wuhan, China. As of March 18, 2020, according to WHO information, the virus has spread to six continents and a total of 179,111 people worldwide were infected with COVID-19, of whom 7,426 have died from the disease. Sharing transparent, valid, and relevant information is one of the cornerstones of the fight to mitigate the impact of this infection. Chinese authors recently published a summary of current knowledge on the epidemiology, clinical manifestations, diagnosis, treatment, and prevention of COVID-19, valid as of March 2, 2020, in the International Journal of Infectious Diseases.
Source: Anti-Infectives 17. 3. 2020

News Importance of pH in Care for Stoma Patients

Maintaining good quality peristomal skin and preventing complications related to the stoma site are integral parts of comprehensive care for patients with stomas. The pH of the skin also plays an important role in this issue, as it can significantly affect the condition of the skin, the development of complications, the quality of life of patients, and consequently impact the economic aspect of stoma care.
Source: Ostomy 19. 3. 2020

News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
Source: Hemophilia with Movement 30. 5. 2022

News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease

Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
Source: Parkinson's Disease 10. 3. 2023

News Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation

A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).
Source: Anticoagulant Treatment 25. 4. 2022

News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study

The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Source: Hematologic Malignancies 10. 8. 2022

News Acquired Hemophilia A Newly Diagnosed in an Elderly Patient − A Case Report

At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.
Source: Acquired Hemophilia 28. 3. 2022

News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients

A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.
Source: Chronic Lymphocytic Leukemia 8. 6. 2020

Journal articles Significance of vitamin D for human health

Author of the article: S. Skácelová Source: Česká revmatologie | 1/2010 14. 4. 2010

News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy

William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.
Source: Chronic Lymphocytic Leukemia 8. 6. 2020

News Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence

A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic sensitization upon allergen exposure. The disease causes significant discomfort for patients and reduces their quality of life, which is why its control is essential for their daily functioning.
Source: Allergic Reactions 24. 5. 2022

News Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level

Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study participants. In the Diabetes Prevention Program (DPP) study, one in five patients in the lifestyle intervention group developed type 2 diabetes within 4 years. However, there are individuals with prediabetes who do not develop diabetes without lifestyle intervention even after 11 years of follow-up. This indicates the need to create more precisely stratified intervention strategies based on the identification of high-risk (HR) and low-risk (LR) individuals with prediabetes. This is precisely the focus of a recently published study by German authors.
Source: Modern Treatment of Diabetes 2. 11. 2022

News Safety of Tofacitinib in Ulcerative Colitis – Combined Results of 6 Studies

At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of ulcerative colitis from a clinical trial program involving 1,157 patients with exposure duration to this therapy of up to 9.2 years were presented.
Source: Intestinal Inflammations 7. 12. 2023

News Vaccination Against COVID-19 in Patients Treated With Anticoagulants

Canadian professional societies and the National Health Service (NHS) in the United Kingdom recommend COVID-19 vaccination even for patients treated with anticoagulants. The benefit of vaccination in these patients significantly outweighs the risk of hematoma associated with intramuscular injection. The recommendation applies to both warfarin and direct oral anticoagulants (DOACs).
Source: Anticoagulant Treatment 11. 10. 2021

News Sport and Programmed Sports Therapy in Hemophiliacs

Sport and physical activity are increasingly becoming an integrated part of the treatment plan for hemophiliacs. It was not long ago that sports were almost forbidden for these patients. The possibilities for active movement were determined by the availability of effective treatment. It has also become clear that sport is not just sport but to some extent also part of the treatment – thanks to the care of experienced physiotherapists.
Source: Hemophilia with Movement 2. 9. 2020

News The Benefit of Dabigatran Over Warfarin Is Greater in Patients with Atrial Fibrillation and Diabetes Than in Nondiabetics

As early as 2015, an analysis of the results of the RE-LY study in patients with atrial fibrillation showed that the reduction in absolute risk of embolic events with dabigatran compared to warfarin is greater in patients with diabetes than in those without diabetes.
Source: Anticoagulant Treatment 24. 4. 2020

Journal articles Predictors of combined hormone contraception choice between Czech and Slovak women

Author of the article: Tomáš Fait Source: Česká gynekologie | 3/2011 11. 7. 2011

News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients

Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.
Source: Anticoagulant Treatment 23. 2. 2022

News Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment

Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.
Source: Cough Therapy 24. 5. 2022

1 7 8 9 10 11 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#